WorldCat Identities

Poizot-Martin, Isabelle

Overview
Works: 22 works in 24 publications in 2 languages and 76 library holdings
Roles: Contributor, Author, Other, Thesis advisor, Opponent
Classifications: RC268.48, 616.979
Publication Timeline
.
Most widely held works by Isabelle Poizot-Martin
VIH/SIDA et cancers : les affections malignes au cours de l'infection par le VIH( Book )

2 editions published in 2001 in French and held by 43 WorldCat member libraries worldwide

Thrombopénie sous Interféron chez le patient co-infecté VIH-VHC : Facteurs prédictifs et mécanismes by Jean-Marie Cournac( Book )

1 edition published in 2012 in French and held by 3 WorldCat member libraries worldwide

LES INFECTIONS A CYTOMEGALOVIRUS AU COURS DU SIDA : EXPERIENCE D'UN TRAITEMENT PAR LE DHPG A L'INSTITUT PAOLI-CALMETTES by Isabelle Poizot-Martin( Book )

1 edition published in 1987 in French and held by 2 WorldCat member libraries worldwide

Sub-therapeutic darunavir concentration and garlic consumption; a "Mediterranean" drug-food interaction, about 2 cases by N Cloarec( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 by for the ANRS CO 13 HEPAVIH Study Group( )

1 edition published in 2010 in English and held by 2 WorldCat member libraries worldwide

Signalisation induite par les molécules HLA de classe II dans les cellules B lymphoïdes normales et malignes folliculaires by Isabelle Poizot-Martin( Book )

2 editions published in 2000 in French and held by 2 WorldCat member libraries worldwide

LES LYMPHOMES B NON-HODGKINIENS FONT PARTIE DES RARES TUMEURS A EXPRIMER DES MOLECULES HLA DE CLASSE II. CECI LEUR PERMET D'INTERAGIR DIRECTEMENT AVEC LES LYMPHOCYTES T CD4+ QUI INFILTRENT LA TUMEUR (TIL-T). LA SIGNALISATION INDUITE PAR LES MOLECULES HLA-DR PEUT INDUIRE SOIT L'APOPTOSE, SOIT LA PROLIFERATION. LA PREMIERE PARTIE DE CE TRAVAIL A ETE D'ETUDIER LE ROLE JOUE PAR LES MOLECULES HLA DE CLASSE II DANS L'INTERACTION ENTRE LES TIL-T CD4+ ET LES LYMPHOCYTES B MALINS DE LYMPHOME FOLLICULAIRE. PAR L'INTERMEDIAIRE DES MOLECULES HLA DE CLASSE II, DES CLONES DE TIL-T CD4+ SONT CAPABLES D'INDUIRE L'ACTIVATION DES LYMPHOCYTES B MALINS ET LEUR ENTREE EN PHASE G1 DU CYCLE CELLULAIRE (INDUCTION DU KI-67). AFIN DE DETERMINER SI LES LYMPHOCYTES B MALINS PRESENTENT DES ANOMALIES INTRINSEQUES LES EMPECHANT DE PROGRESSER DANS LE CYCLE CELLULAIRE, NOUS AVONS ETUDIE DANS UNE DEUXIEME PARTIE L'EFFET D'UNE SIGNALISATION INDUITE PAR LES MOLECULES HLA-DR DANS DES LYMPHOCYTES B NORMAUX. NOUS AVONS D'ABORD MONTRE QUE L'ORIENTATION VERS UNE VOIE APOPTOTIQUE OU PROLIFERATIVE NE DEPEND PAS DE L'ETAT D'ACTIVATION DU LYMPHOCYTE B, MAIS DE LA CAPACITE DU LIGAND A REGROUPER LES MOLECULES HLA-DR A LA SURFACE DE LA CELLULE. EN EFFET, UN AC ANTI-HLA-DR COUPLE A DES BILLES DE SEPHAROSE (QUI MIME LA RELATION AVEC UN LYMPHOCYTE T CD4+) INDUIT LA PROLIFERATION DES LYMPHOCYTES B NORMAUX ALORS QU'UN AC ANTI-HLA-DR COUPLE A UN AC SECONDAIRE, INDUIT L'APOPTOSE, SANS ENTREE PREALABLE DANS LE CYCLE CELLULAIRE. CES RESULTATS MONTRENT QUE DANS LES LYMPHOCYTES B TUMORAUX, L'ENTREE EN CYCLE CORRESPOND BIEN A UN DEBUT DE PROLIFERATION ET NON A UN PRELUDE A L'APOPTOSE. NOUS AVONS REPLACE LA SIGNALISATION HLA-DR DANS UN CONTEXTE PHYSIOLOGIQUE : LES LYMPHOCYTES B RECOIVENT D'ABORD UN SIGNAL INDUIT PAR L'INTERACTION D'UN ANTIGENE SUR LE RECEPTEUR A L'AG DU LYMPHOCYTE B, CE QUI INDUIT UNE PROLIFERATION. ENSUITE, ILS INTERAGISSENT AVEC DES LYMPHOCYTES T CD4+, ENTRAINANT UNE SIGNALISATION PAR LES MOLECULES HLA-DR DANS LE LYMPHOCYTE B. LA PROLIFERATION INDUITE PAR LA STIMULATION DU RECEPTEUR A L'AG EST REGULEE NEGATIVEMENT PAR CO-STIMULATION AVEC UN AC ANTI-HLA-DR LIE A UN AC SECONDAIRE. CECI SE TRADUIT AU NIVEAU DU CYCLE CELLULAIRE, PAR UNE DIMINUTION DE LA PHOSPHORYLATION DE LA PROTEINE PRB DUE A UNE DIMINUTION D'EXPRESSION DES CDK2, 4 ET 6 ET DES CYCLINES E ET A, ET A UN RETARD D'EXPRESSION DE LA CYCLINE D2. LES CDKIS P21 ET P27 NE SONT PAS IMPLIQUES. NOS RESULTATS MONTRENT QU'UN SIGNAL INDUIT PAR HLA-DR EST SUFFISANT POUR INDUIRE UNE PROLIFERATION. L'ABSENCE DE PROLIFERATION DANS LES LYMPHOCYTES B TUMORAUX SUGGERENT FORTEMENT LA PRESENCE D'UNE (OU PLUSIEURS) ANOMALIE(S) INTRINSEQUE(S) EMPECHANT LA PROGRESSION DANS LE CYCLE CELLULAIRE. CE BLOCAGE SEMBLE ETRE GENERAL PUISQU'IL N'AFFECTE PAS QUE LA VOIE HLA DE CLASSE II MAIS EGALEMENT LA VOIE IL4/CD40
Educational intervention and HIV infection: preliminary results by Sylvie Bregigeon( )

1 edition published in 2010 in English and held by 2 WorldCat member libraries worldwide

Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment by Amélie Menard( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination by Dat'AIDS Study Group( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France) by HEPAVIH group( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient by Sylvie Bregigeon( )

1 edition published in 2010 in English and held by 2 WorldCat member libraries worldwide

Hepatitis C treatment initiation in HIV-HCV coinfected patients by the Dat'AIDS study Group( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

L'apport de l'évaluation pharmacocinétique dans le choix des antirétroviraux (nature et dose) chez la personne vivant avec le VIH by Minh Lê( )

1 edition published in 2019 in French and held by 1 WorldCat member library worldwide

En dépit des récentes avancées thérapeutiques, l'infection par le VIH pour être contrôlée nécessite le maintien à vie d'un traitement antirétroviral (ARV). De ce fait, des stratégies d'allègements destinées à réduire la « charge chimique » sont proposées afin de maintenir l'efficacité antivirale tout en améliorant le profil de tolérance. Les compartiments profonds tels que le compartiment central ou le tractus génital se révèlent des sanctuaires de réplication virale et nécessitent pour son contrôle, une pénétration optimisée des ARV depuis la circulation générale. Nous avons d'abord évalué la pénétration de maraviroc, raltégravir et rilpivirine dans les sécrétions génitales (liquide séminal et fluide cervico-vaginal) dans le cadre de stratégies antirétrovirales conventionnelles. Nous avons montré une bonne pénétration séminale de maraviroc et raltégravir et plus faible de rilpivirine. Ensuite, nous avons évalué, d'une part, l'exposition plasmatique de darunavir/ritonavir lors de l'allègement de dose quotidienne administrée de darunavir (essai ANRS-165 DARULIGHT), puis d'autre part, la pénétration séminale de darunavir avant et après allègement. Nous avons également pu caractériser une interaction réciproque complexe d'ordre pharmacocinétique entre darunavir et ritonavir. En effet, aucune différence significative d'exposition plasmatique et séminale n'a pu être démontrée malgré la réduction de moitié de la dose de darunavir. Ces résultats mettent en avant l'absence de linéarité des expositions plasmatiques respectives de darunavir et ritonavir dans l'explication de l'interaction. Enfin, nous avons évalué la pénétration séminale d'étravirine, raltégravir et son métabolite inactif glucuroconjugué, à partir d'une stratégie de maintenance en terme d'allègement du nombre d'ARV (essai ANRS-163 ETRAL). Si aucune interaction médicamenteuse métabolique n'était à redouter entre étravirine et raltégravir, nous avons montré qu'une interaction via les transporteurs d'efflux pouvait modifier la pénétration séminale de raltégravir et de son métabolite glucuroconjugué. Au final, les résultats de l'ensemble de ces travaux ont permis de préciser l'influence de la liaison aux protéines plasmatiques et aux protéines séminales (moindre) dans la pénétration et l'accumulation des ARV dans le tractus génital mâle et l'implication potentielle des transporteurs d'efflux
First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract Background Sparing of antiretroviral drug classes could reduce the toxicity and cost of maintenance treatment for HIV infection. Objectives To evaluate the non-inferiority of efficacy and the safety of lopinavir/ritonavir (r) monotherapy versus a single-tablet regimen of efavirenz, emtricitabine and tenofovir (EFV/FTC/TDF) over 2 years. Methods Adults on stable ART with plasma HIV-1 RNA viral load <50 copies/mL for the past 12 months and no documented treatment failure were randomized to receive either lopinavir/r or EFV/FTC/TDF for 2 years. The primary endpoint was the proportion of patients without treatment failure at week 96 (viral load <50 copies/mL at week 96, confirmed at week 98), without study treatment discontinuation, a new AIDS-defining illness, or death. Results In the ITT analysis, the primary endpoint was reached by, respectively, 64% and 71% of patients in the lopinavir/r (n = 98) and EFV/FTC/TDF arms (n = 97), yielding a difference of -6.8% (lower limit of the 95% two-sided CI: -19.9%). Sanger and UltraDeep sequencing showed the occurrence of PI mutations in the lopinavir/r arm (n = 4) and of NNRTI and/or NRTI mutations in the EFV/FTC/TDF arm (n = 2). No unexpected serious clinical events occurred. Conclusions Lopinavir/r monotherapy cannot be considered non-inferior to EFV/FTC/TDF. PI resistance rarely emerged in the lopinavir/r arm and did not undermine future PI options. Two years of lopinavir/r monotherapy had no deleterious clinical impact when compared with EFV/FTC/TDF
Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

ABSTRACT : N/A: A shift in mortality and morbidity has been observed in people living with human immunodeficiency virus (PLWHIV) from acquired immunodeficiency syndrome (AIDS) to non-AIDS diseases. Lung cancer has the highest incidence rates among all the non-AIDS-defining malignancies and is associated with mortality rates that exceed those of other cancers. Strategies to increase lung cancer survival in PLWHIV are needed. Lung cancer screening with chest LDCT has been shown to be efficient in the general population at risk. The objective of this review is to discuss lung cancer screening with chest computed tomography in PLWHIV. Lung cancer screening in PLWHIV is feasible. Whether PLWHIV could benefit from an age threshold for screening that is earlier than the minimum age of 55 years usually required in the general population still needs further investigation. Studies evaluating smoking cessation programs and how they could be articulated with lung cancer screening programs are also needed in PLWHIV
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Abstract : Abstract: Data on the long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and nevirapine (NVP) are scarce. This combination has the advantage of simplifying treatment and improving long-term tolerance. The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months. ABC/3TC/NVP was compared to ABC/3TC with either ritonavir-boosted darunavir (DRV/r) or ritonavir-boosted atazanavir (ATV/r), unboosted ATV, or tenofovir/emtricitabine (TDF/FTC) with either one of the following: ATV/r, unboosted ATV, DRV/r, efavirenz (EFV), or NVP, in the French prospective multicenter Dat'AIDS cohort. The study enrolled 16, 511 patients treated with following ARV regimens: ABC/3TC/NVP (n = 1089), TDF/FTC/NVP (n = 1542), ABC/3TC/DRV/r (n = 1065), ABC/3TC/ATV/r (n = 1847), ABC/3TC/ATV (n = 563), TDF/FTC/ATV/r (n = 3519), TDF/FTC/DRV/r (n = 2767), TDF/FTC/ATV (n = 419), and TDF/FTC/EFV (n = 3700). Mean follow-up was 36 ± 24 months. Patients treated with ABC/3TC/NVP received this regimen as a switch regimen in 97% of cases. By multivariable analysis, the risk of treatment discontinuation due to VF was similar between ABC/3TC/NVP and other ARV regimens, except for TDF/FTC/ATV and ABC/3TC/ATV, which were associated with a higher risk of treatment interruption due to VF (hazard ratio [HR] 1.99; 95% confidence interval [CI] 1.29-3.06 and HR 2.19; 95% CI 1.51-3.18, respectively). Treatment discontinuation due to ADR was lowest with the ABC/3TC/NVP regimen. Other ARV regimens were associated with a 1.80- to 3.19-fold increase in the risk of treatment discontinuation due to ADR (P <0.0001 for all comparisons). ABC/3TC/NVP as a simplification regimen is a long-term effective regimen with lower discontinuation due to long-term toxicity compared with other standard ARV regimens
Cancer risk in HIV-infected patients( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.91 (from 0.88 for VIH/SIDA e ... to 0.99 for VIH/SIDA e ...)

WorldCat IdentitiesRelated Identities
Alternative Names
Martin Isabelle Poizot-

Poizot, Isabelle

Languages
English (14)

French (8)